Cellectis Profit Margin

Cellectis (CLLS) currently reports a profit margin of -99.28% as of March 2026. That compares with -123.35% in the prior-year period — up 19.5% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Cellectis's profit margin history and peer comparisons.

Cellectis's profit margin increased from -123.35% to -99.28% — a 19.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cellectis's profit margin of -99.28% is lower than the Healthcare sector average of 15.29%. That is roughly 749.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cellectis's current -99.28% should be judged against Healthcare norms (sector average: 15.29%) and against CLLS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -99.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Cellectis, and consider following CLLS for alerts when major investors trade the stock.